What is VirtualScopics Cyclically Adjusted PS Ratio?
Shiller PE for Stocks: The True Measure of Stock Valuation
VirtualScopics Cyclically Adjusted PS Ratio Historical Data
The historical data trend for VirtualScopics's Cyclically Adjusted PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of VirtualScopics's Cyclically Adjusted PS Ratio
For the Medical Devices subindustry, VirtualScopics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
VirtualScopics's Cyclically Adjusted PS Ratio Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, VirtualScopics's Cyclically Adjusted PS Ratio distribution charts can be found below:
* The bar in red indicates where VirtualScopics's Cyclically Adjusted PS Ratio falls into.
VirtualScopics Cyclically Adjusted PS Ratio Calculation
Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
VirtualScopics (NAS:VSCP) Cyclically Adjusted PS Ratio Explanation
Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.
VirtualScopics Cyclically Adjusted PS Ratio Related Terms
Thank you for viewing the detailed overview of VirtualScopics's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
VirtualScopics (VirtualScopics) Business Description
VirtualScopics Inc. is a provider of quantitative imaging for clinical trials serving the pharmaceutical, biotechnology and medical device industries. The Company has developed a software platform for analysis and modeling of both structural and functional medical images. This platform provides information about the biological activity of drugs and devices in clinical trial patients. VirtualScopics is an imaging core lab providing central reads and quantitative imaging solutions for drug and medical device clinical trials for the areas of oncology, rheumatoid arthritis, osteoarthritis, neurology, and cardiovascular studies utilizing MRI, PET, CT, Ultrasound, and X-ray imaging modalities. The Company's image-based measurement and visualization tools enable automated and reproducible measurement of minute changes that occur in anatomic structures in musculoskeletal, oncological, cardiological and neurological diseases. The Company's image analysis provides a degree of accuracy and reproducibility that cannot be duplicated by manual techniques. The Company's quantitative imaging replaces subjective evaluation. It has developed a suite of patented semi-automated tools for the identification and measurement of carotid plaques. Evaluating diseases such as multiple sclerosis (MS), epilepsy, and Alzheimer's requires the identification and measurement of neurological structures and lesions. The Company's competition is largely comprised of a limited number of university research centers that are working on developing the next generation of image analysis tools. The Company's main customers are Novartis, Merck Serono and Amgen. The Company's main competitors are clinical research organizations (CROs) providing clinical trial services to pharmaceutical companies. Healthcare in the United States is heavily regulated by the federal government, and by state and local governments.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
VSCP has been successfully added to your 